cancer risk assessment

  • Placeholder

    Hereditary Cancer Panel 57 ACMG 20 HBOC & 865 literature reviewed Genes

    4.000,00 د.إ

    The **Hereditary Cancer Panel 57 ACMG 20 HBOC & 865 Literature-Reviewed Genes** is a comprehensive genetic test designed to assess hereditary cancer risk. It analyzes **57 key genes**, including the **ACMG 20** and **HBOC-related genes**, alongside **865 literature-reviewed genes**, ensuring a thorough evaluation of cancer predisposition. This panel covers a wide range of hereditary cancers, including **breast, ovarian, colorectal, and more**, providing **clinically actionable insights** for early detection and personalized risk management. Utilizing **advanced sequencing technology**, it delivers **high accuracy and reliability**, making it an essential tool for **patients, healthcare providers, and genetic counselors**. Its unique combination of **expert-curated genes and extensive literature review** enhances diagnostic precision, setting it apart as a **cutting-edge solution for hereditary cancer risk assessment**.

  • Oncotype DX Breast Cancer Test

    Oncotype DX Breast Cancer Test – Personalized Risk Assessment & Treatment Guidance

    35.000,00 د.إ

    The Oncotype DX Breast Cancer (ML) Test is a genomic assay that analyzes the activity of 21 genes in a breast cancer tumor to predict the risk of recurrence and the potential benefit of chemotherapy. Designed for early-stage, hormone receptor-positive, HER2-negative breast cancer patients, it provides a Recurrence Score® result that helps guide personalized treatment decisions. Key benefits include reducing unnecessary chemotherapy, improving patient outcomes, and offering evidence-based insights backed by extensive clinical validation.

  • Tumor Markers Screen (Female)--(CEA, CA 15.3, CA 19.9, CA 125, AFP)

    Tumor Markers Screen (Female)–(CEA, CA 15.3, CA 19.9, CA 125, AFP)

    900,00 د.إ

    Tumor Markers Screen (Female) is a powerful, non-invasive blood test that measures five critical tumor markers: CEA, CA 15.3, CA 19.9, CA 125, and AFP.

    Sample Type : Serum
    Methodology : Chemiluminescence
    TAT : 1 Day

  • Tumor Markers Screen (Male)--(CA 19.9, CEA, PSA-Total, PSA-Free, AFP, BhCG)

    Tumor Markers Screen (Male)–(CA 19.9, CEA, PSA-Total, PSA-Free, AFP, BhCG)

    850,00 د.إ

    Sample Type : Serum
    Methodology : Chemiluminescence
    TAT : 1 Day

WhatsApp Call